Rurioctocog alfa pegol

DB16007ApprovedInvestigationalProtein Based Therapies

Rurioctocog alfa pegol is a pegylated recombinant human coagulation factor VIII used to treat and prevent bleeding episodes in patients 12 years and above with hemophilia A. Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous or secondary events like...

Mechanism: Factor VIII plays an essential role in the intrinsic pathway of the blood coagulation cascade: as a cofactor for activated factor IX (FIXa), factor VIII significantly facilitates the conversion of FIXa-mediated transformation of inactive factor X (FX) to its active form (FXa). FXa then promotes the conversion of prothrombin into thrombin, a key serine protease of the coagulation cascade. Proper blood clotting cannot be achieved with the deficient levels of factor VIII, leading to increased excessive bleeding spontaneously or as a result of accidental or surgical trauma. Hemophilia A is an X-chromosomal linked hereditary disorder of blood coagulation due to defects in the F8C gene that encodes coagulation factor VIII, leading to decreased production of functional factor VIII.
Rurioctocog alfa pegol is a pegylated recombinant human factor VIII that aims to restore the plasma levels and hemostatic activity of functional factor VIII. It can be used for both prophylactic or on-demand treatment of bleeding episodes associated with hemophilia A.
Curator reviewed · 4 references
Primary indication: Rurioctocog alfa pegol is indicated for the treatment and prophylaxis of bleeding in patients 12 years and above with hemophilia A (congenital factor VIII deficiency).Curator reviewed · 2 structured indications
Formula / weight: C₁₂₂₅₇H₁₇₈₆₃N₃₂₂₀O₃₅₅₂S₈₃ · 269812.0 Da (approximate)
First approval: European Union, 2020
Also known as: Adynovate · Antihemophilic factor (recombinant), pegylated (20 kda) · Antihemophilic factor (recombinant), pegylated (mw 20000) · Antihemophilic factor, pegylated (mw 20000) human sequence recombinant · PEGylated Recombinant Factor VIII
Code names: BAX-855 · SHP-660 · TAK-660
Brand names: Adynovi

Resolves to

Compound

UNII5X3GF74R79CAS1417412-83-9

Targets

P04275VWFP00451F8

What you can answer from here — as of September 05, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

128Drug interactionsStructured to mechanism, not free text

10Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

23Marketed productsAcross 2 countries and 2 labellers

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rurioctocog alfa pegol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account